BioAI4LCMS

The BioAI4LCMS project unites Genedata AG with leading academic partners, the University of Bern and HES-SO, to develop a new generation of AI-assisted software solutions for liquid chromatography–mass spectrometry (LC–MS). The initiative aims to automate and optimize complex LC–MS workflows used in biopharmaceutical research — from method development to data interpretation — by integrating adaptive artificial intelligence and machine learning algorithms. Using self-learning models and heuristic optimization, the platform will continuously refine data processing, peak detection, and analytical accuracy. Ultimately, BioAI4LCMS will enable faster, more consistent, and scalable LC–MS analyses, supporting the biopharmaceutical industry in advancing therapeutic discovery, molecular characterization, and quality monitoring. The complexity of LC–MS workflows demanding deep expertise and extensive manual effort, will be transformed through this AI-assisted approach — making advanced analytical science more accessible, intuitive, and empowering for a broader community of users.

This project is an interdisciplinary collaboration between the Software Engineering Group of the University of Bern, the HES-SO Valais–Wallis School of Engineering and the company Genedata.

BioAI4LCMS will redefine how the biopharmaceutical industry processes and interprets LC–MS data, bridging the gap between expert-driven analysis and automated intelligence. By integrating Machine learning based optimization algorithms and specialized artificial intelligence algorithms into Genedata Expressionist, the project is redefining how complex LC–MS proteomics data are processed, interpreted, and optimized. What once required deep expert knowledge and manual fine-tuning will become a self-learning, adaptive workflow — delivering faster, reproducible, and higher-quality results across instruments and laboratories. Through automated data interpretation, dynamic noise reduction, and intelligent peak detection, BioAI4LCMS enables a new level of scalability and standardization in LC–MS–based biopharmaceutical analysis. This innovation empowers scientists to focus on decision-making, shortening time-to-insight and enhancing regulatory confidence. By transforming advanced LC–MS proteomics into a more intuitive, accessible, and intelligent platform, BioAI4LCMS paves the way for next-generation biopharma workflows — accelerating therapeutic discovery, improving molecular characterization, and ensuring consistent product quality in a rapidly evolving industry.